Navigation Links
Conatus Pharmaceuticals Completes the Second Closing of its Series B Private Placement Financing

SAN DIEGO, April 12, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced an additional $7.5 million investment by MPM Capital of South San Francisco, CA.  The Series B Preferred Stock financing is now closed with a total of $32.5 million of capital raised. The first closing was completed in early February, 2011.  Jim Scopa from MPM will join the Conatus Board of Directors.

Conatus will use the proceeds to advance the clinical development of CTS-1027, a novel clinical-stage drug candidate the Company licensed from F. Hoffman-La Roche, Ltd. and the subject of multiple Phase 2 clinical trials in hepatitis C (HCV)-infected patients.

"We've watched the progress at Conatus and believe that CTS-1027 could make a significant difference in the treatment of HCV infection.  MPM also expects to provide other resources, both strategic and clinical, to assist the management team in the execution of its business plan", said Jim Scopa, Managing Director of MPM Capital.

"The additional investment by MPM enables Conatus to move ahead assertively with its confirming Phase 2b clinical trial of CTS-1027 started in January 2011 as well as allowing for a thorough evaluation of the development compounds of Idun Pharmaceuticals acquired in 2010," said Steven J. Mento, Ph.D.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology. Conatus' lead drug candidate, CTS-1027 is in multiple Phase 2 clinical trials for the treatment of hepatitis C virus (HCV).  Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer. For additional information, please visit

SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
2. Conatus Pharmaceuticals Will Display HCV Clinical Trial Data at the International Liver Congress™ (EASL) in March
3. Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
4. Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
5. Conatus Pharmaceuticals Acquires Pfizers Idun Subsidiary
6. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
7. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
8. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
10. MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
11. Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Post Your Comments:
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from reveals that behind the tendency to set low expectations ...
Breaking Medicine News(10 mins):